Does Rallies show 13F holders for IART?

Yes. Rallies tracks hedge fund and 13F ownership data for IART, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IART research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IART. It does not provide personalized investment advice.

IART (Integra LifeSciences Holdings) Stock Analysis - Hedge Fund Holdings

Integra LifeSciences Holdings (IART) is a publicly traded Healthcare sector company. As of May 21, 2026, IART trades at $15.22 with a market cap of $1.10B and a P/E ratio of -2.33. IART moved +7.06% today. Year to date, IART is +22.53%; over the trailing twelve months it is +15.54%. Its 52-week range spans $8.70 to $27.13. Analyst consensus is neutral with an average price target of $15.60. Rallies surfaces IART's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IART stock?

Hedge funds tracked by Rallies that own IART include Maverick Capital, Panagora Asset, Centerbook Partners, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Integra LifeSciences Holdings.

IART Key Metrics

Key financial metrics for IART
Metric	Value
Price	$15.22
Market Cap	$1.10B
P/E Ratio	-2.33
EPS	$-6.46
Dividend Yield	0.00%
52-Week High	$27.13
52-Week Low	$8.70
Volume	10
Avg Volume	0
Revenue (TTM)	$1.64B
Net Income	$-495.80M
Gross Margin	51.94%

Top Hedge Funds Holding IART

Maverick Capital holds 72.11K shares of IART, changed +665.56% as of Mar 31, 2026.
Panagora Asset holds 38.95K shares of IART, changed -12.66% as of Mar 31, 2026.
Centerbook Partners holds 30.57K shares of IART, changed +0.00% as of Mar 31, 2024.
Bridgewater Associates holds 29.53K shares of IART, changed -73.94% as of Sep 30, 2024.
Pinebridge Investments holds 4.07K shares of IART, changed +0.00% as of Jun 30, 2023.

Latest IART News

Integra sees 2.4% Q1 revenue growth to $391.9M and names new CEO — May 5, 2026
Integra to Present 985-Case PriMatrix Dermal Scaffold Data at April Meetings — Apr 7, 2026
Integra LifeSciences Guides Q1 Revenue 2.8% Below Estimates, Margins Plunge — Feb 26, 2026
Integra LifeSciences Q4 Revenues Dip 1.7%, Adjusted EPS Falls to $0.83 — Feb 26, 2026
Integra LifeSciences Sees Revenue Guidance Miss, Forecasting 2.7% Sales Drop — Feb 25, 2026

Recent IART Insider Trades

GRAVES JEFFREY A bought 9.00K (~$102.15K) on Nov 5, 2025.
Schwartz Eric sold 4.07K (~$100.10K) on Dec 3, 2024.
McBreen Michael J. sold 1.70K (~$41.06K) on Dec 2, 2024.

IART Analyst Consensus

8 analysts cover IART: 0 strong buy, 1 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $15.60.

Common questions about IART

Who owns IART stock?: Hedge funds tracked by Rallies that own IART include Maverick Capital, Panagora Asset, Centerbook Partners, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Integra LifeSciences Holdings.
Does Rallies show 13F holders for IART?: Yes. Rallies tracks hedge fund and 13F ownership data for IART, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IART research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IART. It does not provide personalized investment advice.